Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary...(st marketing decisions by regulatory aut...),Health

Date:8/30/2009

st marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2008. Other than as required by applicable law, Sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

'/>"/>

SOURCE Sanofi-aventis Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty
2. Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk
3. Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study
4. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
5. CardioDx Completes Validation Study of First-Of-Its-Kind Genomic Test for Coronary Artery Disease
6. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
7. WorldHeart Receives US Clinical Study Approval for the Levacor(TM) VAD
8. Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease
9. Study Links Fetal Fibronectin Testing with Changes in Management Decisions for Symptomatic and Asymptomatic Women at Risk for Preterm Birth
10. Study of Lacrisert(R) Dry Eye Insert Published in The Ocular Surface
11. Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComms CRO Preferred Program